Study guide

2.1 Physicochemical Principles, Solubility, Ionization, and Stability

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

2.1 Physicochemical Principles, Solubility, Ionization, and Stability

Key Takeaways Explain This Topic AI

Polymorphic crystal forms have identical chemical formulas but distinct physical properties, including melting points, solubilities, and dissolution rates.

The Henderson-Hasselbalch equation quantifies drug ionization; un-ionized species permeate lipophilic biological membranes, whereas ionized species are trapped in aqueous compartments.

The Noyes-Whitney equation demonstrates that dissolution rate is directly proportional to particle surface area and saturation solubility, and inversely proportional to the diffusion layer thickness.

Hydrolysis, oxidation, and photolysis represent the primary chemical degradation pathways, stabilized by buffer optimization, sacrificial antioxidants, and light-resistant packaging.

Zero-order degradation maintains a constant reaction rate independent of drug concentration, whereas first-order degradation exhibits a rate directly proportional to residual concentration.

Last updated: August 2026

Physicochemical Properties and Solid-State Science

The therapeutic efficacy of any pharmaceutical active pharmaceutical ingredient (API) depends fundamentally on its intrinsic physicochemical properties. The solid state of a drug molecule dictates its thermodynamic stability, processing behavior, apparent solubility, and biological dissolution rate.

Crystal Forms, Polymorphism, and Amorphous States

Polymorphism refers to the ability of a solid chemical compound to exist in more than one crystalline form with distinct molecular packing or conformational arrangements in the crystal lattice. Although polymorphs are chemically identical, their physical properties vary substantially:

Thermodynamic Stability: The stable polymorph possesses the lowest free energy, highest melting point, and lowest equilibrium solubility. Metastable polymorphs exhibit higher free energy, lower melting points, higher apparent solubilities, and faster dissolution rates.

Bioavailability Implications: If a drug undergoes polymorphic transition during manufacturing or storage from a metastable form to a less soluble stable form, dramatic reductions in bioavailability can occur. A classic pharmaceutical example is ritonavir ( Norvir ), which was temporarily withdrawn from the market when an unexpected, thermodynamically stable Form II polymorph precipitated out of the commercial oral liquid formulation.

Amorphous Solids: Amorphous forms lack long-range three-dimensional crystal order. Because no crystal lattice energy must be overcome during dissolution, amorphous drugs possess significantly higher apparent solubility and faster dissolution rates than crystalline forms. However, amorphous materials are thermodynamically metastable and prone to devitrification (recrystallization) over product shelf-life, necessitating stabilization via polymeric solid dispersions.

Hydrates and Solvates (Pseudopolymorphism): When solvent molecules are incorporated within the crystal lattice, the resulting solid is a solvate (or a hydrate when the solvent is water). Generally, anhydrous crystal forms exhibit higher aqueous solubility and faster dissolution rates than their corresponding hydrates (e.g., anhydrous theophylline dissolves faster than theophylline monohydrate) because hydrate crystal lattices are already partially stabilized by water-water intermolecular interactions. Solid-State Forms:

  • |-- Crystalline
  • | |-- Stable Polymorph (Lowest free energy, lowest solubility, slowest dissolution)
  • | |-- Metastable Polymorph (Higher free energy, higher solubility, faster dissolution)
  • | |-- Solvates / Hydrates (Water in crystal lattice; hydrates usually dissolve slower than anhydrates)
  • |-- Amorphous (No crystal lattice, highest apparent solubility, thermodynamically unstable)
  • Ionization, pKa, and the Henderson-Hasselbalch Relationship

Most active pharmaceutical ingredients are weak organic acids or weak organic bases. Their degree of ionization in aqueous biological fluids is governed by the solution pH and the drug's acid dissociation constant ( p K a \text{p}K_a p K a ​ ).

Henderson-Hasselbalch Equations

For a weak acid ( HA ⇌ H + + A − \text{HA} \rightleftharpoons \text{H}^+ + \text{A}^- HA ⇌ H + + A − ): pH = p K a + log ⁡ ( [ A − ] [ HA ] ) = p K a + log ⁡ ( ionized un-ionized ) \text{pH} = \text{p}K_a + \log\left(\frac{[\text{A}^-]}{[\text{HA}]}\right) = \text{p}K_a + \log\left(\frac{\text{ionized}}{\text{un-ionized}}\right) pH = p K a ​ + lo g ( [ HA ] [ A − ] ​ ) = p K a ​ + lo g ( un-ionized ionized ​ )

For a weak base ( BH + ⇌ H + + B \text{BH}^+ \rightleftharpoons \text{H}^+ + \text{B} BH + ⇌ H + + B ): pH = p K a + log ⁡ ( [ B ] [ BH + ] ) = p K a + log ⁡ ( un-ionized ionized ) \text{pH} = \text{p}K_a + \log\left(\frac{[\text{B}]}{[\text{BH}^+]}\right) = \text{p}K_a + \log\left(\frac{\text{un-ionized}}{\text{ionized}}\right) pH = p K a ​ + lo g ( [ BH + ] [ B ] ​ ) = p K a ​ + lo g ( ionized un-ionized ​ )

Ionization Benchmarks and Clinical Rules of Thumb

pH Relative to p K a \text{p}K_a p K a ​ Weak Acid (% Ionized) Weak Base (% Ionized)

pH = p K a − 2 \text{pH} = \text{p}K_a - 2 pH = p K a ​ − 2 0.99 % 0.99\% 0.99% (predominantly un-ionized) 99.0 % 99.0\% 99.0% (predominantly ionized)

pH = p K a − 1 \text{pH} = \text{p}K_a - 1 pH = p K a ​ − 1 9.09 % 9.09\% 9.09% 90.9 % 90.9\% 90.9%

pH = p K a \text{pH} = \text{p}K_a pH = p K a ​ 50.0 % 50.0\% 50.0% (equal ionized & un-ionized) 50.0 % 50.0\% 50.0% (equal ionized & un-ionized)

pH = p K a + 1 \text{pH} = \text{p}K_a + 1 pH = p K a ​ + 1 90.9 % 90.9\% 90.9% 9.09 % 9.09\% 9.09%

pH = p K a + 2 \text{pH} = \text{p}K_a + 2 pH = p K a ​ + 2 99.0 % 99.0\% 99.0% (predominantly ionized) 0.99 % 0.99\% 0.99% (predominantly un-ionized)

The pH-Partition Hypothesis and Ion Trapping

According to the pH-partition hypothesis , biological membranes are selectively permeable to the lipid-soluble, un-ionized form of a drug molecule. The ionized species, bearing a formal charge, is surrounded by a hydration shell that severely impedes passive transcellular lipid diffusion.

Clinical Application (Urinary Ion Trapping):

Weak Acid Poisoning (e.g., Acetylsalicylic Acid, Phenobarbital): Administration of IV sodium bicarbonate alkalinizes the urine to pH 7.5 to 8.0 \text{pH } 7.5\text{ to }8.0 pH 7.5 to 8.0 . Because the urine pH rises well above the drug's p K a \text{p}K_a p K a ​ , the weak acid converts almost entirely into its ionized conjugate base ( A − \text{A}^- A − ), preventing passive tubular reabsorption and accelerating renal elimination.

Weak Base Poisoning (e.g., Amphetamines): Acidification of the urine with ammonium chloride converts the base into its protonated cation ( BH + \text{BH}^+ BH + ), trapping it in the tubular lumen to enhance clearance.

Solubility and Dissolution Science

Solubility is defined as the maximum concentration of solute that dissolves in a given volume of solvent at a specific temperature and pressure at thermodynamic equilibrium. Intrinsic solubility ( S 0 S_0 S 0 ​ ) is the equilibrium solubility of the purely un-ionized drug species.

Total Apparent Solubility

For weak acids: S t = S 0 ⋅ [ 1 + 10 ( pH − p K a ) ] S_t = S_0 \cdot \left[1 + 10^{(\text{pH} - \text{p}K_a)}\right] S t ​ = S 0 ​ ⋅ [ 1 + 1 0 ( pH − p K a ​ ) ]

For weak bases: S t = S 0 ⋅ [ 1 + 10 ( p K a − pH ) ] S_t = S_0 \cdot \left[1 + 10^{(\text{p}K_a - \text{pH})}\right] S t ​ = S 0 ​ ⋅ [ 1 + 1 0 ( p K a ​ − pH ) ]

The Noyes-Whitney Equation of Dissolution

The rate at which a solid dissolves in a solvent is described by the Noyes-Whitney equation : d M d t = D ⋅ A ⋅ ( C s − C b ) h \frac{dM}{dt} = \frac{D \cdot A \cdot (C_s - C_b)}{h} d t d M ​ = h D ⋅ A ⋅ ( C s ​ − C b ​ ) ​

Where:

d M d t \frac{dM}{dt} d t d M ​ is the dissolution rate (mass dissolved per unit time).

D D D is the diffusion coefficient of the solute in the dissolution medium.

A A A is the effective surface area of the dissolving solid particles.

C s C_s C s ​ is the saturation solubility of the drug in the stagnant diffusion layer.

C b C_b C b ​ is the drug concentration in the bulk solution.

h h h is the thickness of the stagnant hydrodynamic diffusion layer surrounding the dissolving particle.

Sink Conditions: When the bulk volume is large and the drug is continuously absorbed or removed such that C b < 0.15 ⋅ C s C_b < 0.15 \cdot C_s C b ​ < 0.15 ⋅ C s ​ , ( C s − C b ) ≈ C s (C_s - C_b) \approx C_s ( C s ​ − C b ​ ) ≈ C s ​ , simplifying the equation to d M d t = D ⋅ A ⋅ C s h \frac{dM}{dt} = \frac{D \cdot A \cdot C_s}{h} d t d M ​ = h D ⋅ A ⋅ C s ​ ​ .

Formulation Strategies to Enhance Dissolution and Solubility

Particle Size Reduction (Micronization / Nanosuspensions): Dramatically increases the total effective surface area ( A A A ), increasing d M d t \frac{dM}{dt} d t d M ​ .

Salt Formation: Converting a free acid or free base into an ionized salt form (e.g., naproxen sodium vs. naproxen) elevates the microenvironmental saturation solubility ( C s C_s C s ​ ) within the diffusion layer.

Cosolvency: Introducing water-miscible organic solvents (ethanol, propylene glycol, polyethylene glycol 400) lowers the dielectric constant of the medium to dissolve poorly soluble lipophilic compounds.

Cyclodextrin Complexation: Cyclic oligosaccharides (e.g., hydroxypropyl- β \beta β -cyclodextrin) possess a hydrophobic central cavity that encapsulates lipophilic drug molecules while presenting a hydrophilic outer surface to water.

Solid Dispersions and Self-Emulsifying Systems (SEDDS): Dispersing the API in hydrophilic polymers (e.g., povidone, copovidone) or isotropic lipid-surfactant mixtures that spontaneously form microemulsions in gastrointestinal fluids.

Chemical Degradation Pathways and Formulation Stabilization

Active pharmaceutical ingredients undergo chemical decomposition during manufacturing, storage, and reconstitution. Formulators must identify the degradation pathways to design stable dosage forms.

Degradation Mechanism Susceptible Functional Groups Pharmaceutical Examples Stabilization Strategies

Hydrolysis Esters, amides, lactams, lactones Penicillins, cephalosporins, aspirin, lidocaine Lyophilization, dry powder for reconstitution, pH buffering at rate minimum, desiccants

Oxidation Phenols, catechols, thiols, conjugated double bonds Epinephrine, morphine, dopamine, ascorbic acid Oxygen displacement (nitrogen purge), sacrificial antioxidants (sodium metabisulfite, BHT), chelating agents (EDTA), amber containers

Photolysis Nitro groups, conjugated dienes, heterocycles Sodium nitroprusside, nifedipine, furosemide Light-resistant amber glass, opaque secondary packaging, aluminum foil overwraps

Epimerization / Racemization Asymmetric chiral carbons Tetracycline (forming 4-epitetracycline), pilocarpine Strict pH control, storage at low temperatures, anhydrous formulation

Reaction Kinetics and Shelf-Life Determination

Chemical degradation kinetics describe the rate of drug decomposition as a function of time and reactant concentration.

Zero-Order Kinetics

The reaction rate is independent of drug concentration: − d C d t = k 0 ⟹ C t = C 0 − k 0 ⋅ t -\frac{dC}{dt} = k_0 \implies C_t = C_0 - k_0 \cdot t − d t d C ​ = k 0 ​ ⟹ C t ​ = C 0 ​ − k 0 ​ ⋅ t

Half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ): t 1 / 2 = 0.5 ⋅ C 0 k 0 t_{1/2} = \frac{0.5 \cdot C_0}{k_0} t 1/2 ​ = k 0 ​ 0.5 ⋅ C 0 ​ ​

Shelf-life ( t 90 t_{90} t 90 ​ , time to 90 % 90\% 90% remaining potency): t 90 = 0.1 ⋅ C 0 k 0 t_{90} = \frac{0.1 \cdot C_0}{k_0} t 90 ​ = k 0 ​ 0.1 ⋅ C 0 ​ ​

Clinical Note: Zero-order degradation is typical of suspensions, where dissolved drug is continuously replaced by dissolving solid particles, keeping the solution concentration saturated and constant.

First-Order Kinetics

The reaction rate is directly proportional to drug concentration: − d C d t = k 1 ⋅ C ⟹ ln ⁡ ( C t ) = ln ⁡ ( C 0 ) − k 1 ⋅ t or C t = C 0 ⋅ e − k 1 ⋅ t -\frac{dC}{dt} = k_1 \cdot C \implies \ln(C_t) = \ln(C_0) - k_1 \cdot t \quad \text{or} \quad C_t = C_0 \cdot e^{-k_1 \cdot t} − d t d C ​ = k 1 ​ ⋅ C ⟹ ln ( C t ​ ) = ln ( C 0 ​ ) − k 1 ​ ⋅ t or C t ​ = C 0 ​ ⋅ e − k 1 ​ ⋅ t

Half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ): t 1 / 2 = ln ⁡ ( 2 ) k 1 = 0.693 k 1 t_{1/2} = \frac{\ln(2)}{k_1} = \frac{0.693}{k_1} t 1/2 ​ = k 1 ​ l n ( 2 ) ​ = k 1 ​ 0.693 ​ (independent of initial concentration C 0 C_0 C 0 ​ )

Shelf-life ( t 90 t_{90} t 90 ​ ): t 90 = − ln ⁡ ( 0.90 ) k 1 = 0.1054 k 1 t_{90} = \frac{-\ln(0.90)}{k_1} = \frac{0.1054}{k_1} t 90 ​ = k 1 ​ − l n ( 0.90 ) ​ = k 1 ​ 0.1054 ​

Clinical Note: Most homogeneous liquid formulations and drug solutions degrade via pseudo-first-order kinetics.

Temperature Effects and the Arrhenius Equation

Reaction rates accelerate exponentially with increasing temperature according to the Arrhenius equation : k = A ⋅ e − E a R ⋅ T ⟹ ln ⁡ ( k 2 k 1 ) = E a R ⋅ ( 1 T 1 − 1 T 2 ) k = A \cdot e^{-\frac{E_a}{R \cdot T}} \implies \ln\left(\frac{k_2}{k_1}\right) = \frac{E_a}{R} \cdot \left(\frac{1}{T_1} - \frac{1}{T_2}\right) k = A ⋅ e − R ⋅ T E a ​ ​ ⟹ ln ( k 1 ​ k 2 ​ ​ ) = R E a ​ ​ ⋅ ( T 1 ​ 1 ​ − T 2 ​ 1 ​ )

Where E a E_a E a ​ is the activation energy, R R R is the universal gas constant ( 8.314 J / ( mol ⋅ K ) 8.314\text{ J}/(\text{mol}\cdot\text{K}) 8.314 J / ( mol ⋅ K ) ), and T T T is absolute temperature in Kelvin.

Accelerated Stability Testing (ICH Q1A / Health Canada Standards):

Long-term storage: 25 ∘ C ± 2 ∘ C / 60 % RH ± 5 % RH 25^\circ\text{C} \pm 2^\circ\text{C} / 60\%\text{ RH} \pm 5\%\text{ RH} 2 5 ∘ C ± 2 ∘ C /60% RH ± 5% RH

Accelerated storage: 40 ∘ C ± 2 ∘ C / 75 % RH ± 5 % RH 40^\circ\text{C} \pm 2^\circ\text{C} / 75\%\text{ RH} \pm 5\%\text{ RH} 4 0 ∘ C ± 2 ∘ C /75% RH ± 5% RH (6 months testing predicts real-time shelf life using Arrhenius extrapolation)